Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study.

Oncologist · 2025 · PMC12497480 · PMID 40924546

Europe PMC DOI

hedged sentence

0.3430

closest p · 6.9× alpha

0.3430

boldest claim

The sentences

showed a trendP = .343not close (p > 0.1)

Median PFS showed a trend favoring THPy (19.80 months vs 15.57 months; Log-rank P = .343).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.